GoodRx, Criteo $32 million settlement set to be approved by US judge on third try | MLex | Specialist news and analysis on legal risk and regulation

A US judge is set to approve a $32 million settlement for GoodRx and Criteo, resolving privacy allegations. This is the third iteration of the settlement. Both companies are involved in the case.

Original reporting
Published Sep 3, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 12:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$GDRX
Neutral
medium confidence
Mentioned
$GDRX · $CRTO
Relevance
7/10
AlphAI data visualization · based on mlex.com
Decision brief

The 30-second read

$GDRXNeutralLow
01

Why it matters

Resolution of the privacy case removes a legal cloud, but the settlement size is modest relative to both companies' valuations.

02

Market read

Legal settlement news with limited immediate price impact but relevant for risk assessment in the health‑tech and ad‑tech sectors.

03

What to watch

Potential future regulatory actions could outweigh the immediate settlement impact.

Relevance 7/10Novelty 7/10Timing: preliminary approval today

Background

The article reports a third‑iteration $32 million settlement to resolve privacy allegations against GoodRx and Criteo, pending a U.S. judge's preliminary approval.

Company-level read

Ticker impact

$GDRXNeutralMedium confidence
Context

GoodRx is part of a $32 million privacy settlement awaiting preliminary approval.

Expected impact

small upside if settlement is viewed favorably, limited downside risk.

Evidence & confidence

Settlement amount is moderate; market may price in reduced litigation exposure.

$CRTONeutralMedium confidence
Context

Criteo is involved in the same $32 million privacy settlement with GoodRx.

Expected impact

minor positive effect as regulatory uncertainty lifts.

Evidence & confidence

Settlement size is modest relative to Criteo's market cap; impact likely limited.

Market effects

Highlights ongoing privacy enforcement risk for health‑tech and ad‑tech sectors.

U.S. and EU privacy regulators may see increased scrutiny of similar firms.

Sets precedent for cross‑border privacy settlements affecting multinational tech companies.

Counterpoint

Settlement may be seen as a cost without substantive change, limiting price reaction.

Key entities

  • GoodRx

    Telemedicine platform facing privacy lawsuit.

  • Criteo

    French ad‑tech firm co‑defendant in the settlement.

Related articles

$APPMed

AppLovin Reportedly in Talks to Acquire Ad-Tech Firm Criteo

AppLovin is reportedly in talks to acquire Criteo, a Paris-based ad-tech firm. Other potential buyers include Vista Equity Partners and Quinti Capital. Criteo has hired an investment bank to explore strategic options, including a sale. The deal may be announced by the end of 2026, but no agreement is certain. No financial details were disclosed.

$APPMed

AppLovin in talks to acquire ad-tech peer Criteo, Reuters reports

AppLovin (APP) is in talks to acquire Criteo (CRTO), according to Reuters. Both companies' shares fell following the news. Criteo has been exploring strategic alternatives, including a sale, after earlier interest from private equity firms. The deal would expand AppLovin's reach beyond mobile gaming and apps, but investors reacted cautiously. No financial terms or guarantees were disclosed.